BIIB - NASDAQ
Biogen Inc.
$195.96
+3.8%Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotBiogen Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Net Profit Margin
Strong net margins indicate efficient operations and favorable tax/interest management.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Biogen Inc. Income Statement
BIIB • NASDAQ
| Biogen Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
9.8B | 9.7B | 9.8B | 10.2B | 11B | 13.4B | 14.4B | 13.5B | 12.3B | 11.4B | 10.8B | 9.7B | 6.9B | 5.5B | 5B | 4.7B | 4.4B | 4.1B | 3.2B | 2.7B | |
GROSS PROFIT | ||||||||||||||||||||
(2.9B) | (2.3B) | (2.5B) | (2.3B) | (2.1B) | (1.8B) | (2B) | (1.8B) | (1.6B) | (1.4B) | (1.2B) | (1.2B) | (857.7M) | (545.5M) | (466.8M) | (400.3M) | (382.1M) | (402M) | (335.2M) | (274.4M) | |
6.9B | 7.4B | 7.3B | 7.9B | 8.9B | 11.6B | 12.4B | 11.6B | 10.6B | 10B | 9.5B | 8.5B | 6.1B | 5B | 4.6B | 4.3B | 4B | 3.7B | 2.8B | 2.4B | |
OPERATING INCOME | ||||||||||||||||||||
(5B) | (4.9B) | (5.2B) | (5B) | (6.1B) | (7B) | (5.4B) | (5.7B) | (5.3B) | (4.9B) | (4.6B) | (4.6B) | (3.6B) | (3.1B) | (2.9B) | (3.1B) | (2.7B) | (2.5B) | (2.1B) | (2B) | |
(2.4B) | (2.4B) | (2.5B) | (2.4B) | (2.7B) | (2.5B) | (2.4B) | (2.1B) | (1.9B) | (1.9B) | (2.1B) | (2.2B) | (1.7B) | (1.3B) | (1.1B) | (1B) | (1.1B) | (1.1B) | (776.1M) | (685.1M) | |
(2B) | (2.5B) | (2.7B) | (2.6B) | (3.4B) | (4.5B) | (2.8B) | (2.7B) | (2.4B) | (2B) | (2B) | (1.9B) | (1.5B) | (1.4B) | (1.2B) | (1.2B) | (1.3B) | (1.1B) | (925.2M) | (718.4M) | |
1.9B | 2.5B | 2.1B | 2.9B | 2.8B | 4.6B | 7B | 5.9B | 5.3B | 5.2B | 4.9B | 4B | 2.5B | 1.8B | 1.7B | 1.2B | 1.3B | 1.2B | 779.8M | 440M | |
PRE-TAX INCOME | ||||||||||||||||||||
(246M) | (250.3M) | (246.9M) | (246.6M) | (253.6M) | (222.5M) | (187.4M) | (200.6M) | (250.8M) | (260M) | (95.5M) | (29.5M) | (31.9M) | (36.5M) | (33M) | (36.1M) | (35.8M) | (52M) | (40.5M) | (871K) | |
-158.2M | -182.7M | 29.6M | -157.3M | -242.6M | -180.5M | -67.4M | -88.1M | -172.3M | -196.6M | -73.4M | -17.3M | -23.7M | -7M | -13.8M | -13.8M | 12.7M | 20.1M | 63.1M | 100.3M | |
(647.7M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (250.5M) | (929.2M) | (988.1M) | (940.7M) | (506.5M) | (434.2M) | (391.1M) | (0.0) | (581.4M) | (787.1M) | (289.8M) | (348.5M) | (355.4M) | (565.2M) | |
-476M | -584.3M | -800.5M | 705.3M | -1B | 459.8M | 3.9M | 11M | -217M | -218.7M | -136.2M | -40.9M | -52.2M | 12.1M | -13.5M | -19M | 37.3M | -57.7M | 130.8M | 52.1M | |
1.4B | 1.9B | 1.3B | 3.6B | 1.8B | 5.1B | 7B | 5.9B | 5.1B | 4.9B | 4.8B | 3.9B | 2.5B | 1.9B | 1.7B | 1.2B | 1.3B | 1.2B | 910.6M | 492.2M | |
NET INCOME | ||||||||||||||||||||
(108.1M) | (273.8M) | (135.3M) | (632.8M) | (52.5M) | (992.3M) | (1.2B) | (1.4B) | (2.5B) | (1.2B) | (1.2B) | (989.9M) | (601M) | (470.6M) | (444.5M) | (331.3M) | (355.6M) | (365.8M) | (272.4M) | (278.4M) | |
1.3B | 1.6B | 1.2B | 3B | 1.6B | 4B | 5.9B | 4.4B | 2.5B | 3.7B | 3.5B | 2.9B | 1.9B | 1.4B | 1.2B | 1B | 970.1M | 783.2M | 638.2M | 217.5M |
SEC Filings
BIIB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 29, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 06, 2026 | April 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 11, 2026 | March 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 11, 2026 | February 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 06, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 06, 2026 | February 06, 2026 | 2026 |
Related Guides
Continue your BIIB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.